SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSCLC
As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms
Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received approval from the US Food and Drug Administration (FDA) for Langlara (insulin glargine-aldy), an interchangeable biosimilar of Lantus (insulin glargine).
The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in
iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,